By Class: 2018-2019

Class

Brand name

Generic/ common name

Status

Genotype  (FDA and Off-Label)

Approved for HIV/HCV co-infection?

Manufacturer

Nucleoside analog

Moderiba

ribavirin  (RBV)

Approved

1 2 3 4 5 6

Yes

AbbVie

Ribasphere

ribavirin  (RBV)

Approved

1 2 3 4 5 6

Yes

Kadmon

NS3/4A protease inhibitor

Olysio

simeprevir,  (SIM )

Approved

1

No

Janssen

Viekira XR; Technivie

paritaprevir,  (P)

Approved

Viekira XR: 1 Technivie: 4

Yes

AbbVie

Zepatier

Grazoprevir,  (GZR)

Approved

1 4

Yes

Merck

Vosevi

Voxilaprevir,  (VOX)

Approved

1 2 3 4 5 6

No, but off-label use is okay

Gilead Sciences

Mavyret

glecaprevir,  (G)

Approved

1 2 3 4 5 6

Yes

AbbVie

Nucleoside and Nucleotide NS5B polymerase inhibitor

Sovaldi;

Harvoni;

Epclusa

sofosbuvir,  (SOF)

Approved

1 2 3 4 5 6

Yes

Gilead Sciences

NS5A inhibitorx

Harvoni

ledipasvir, (LDV)

Approved

1 4 5 6

Yes

Gilead Sciences

Daklinza

daclatasvir,  (DCV)

Approved

1 3

Yes

Bristol-Myers Squibb

Viekira XR; Technivie

ombitasvir,  (OMB)

Approved

Viekira XR: 1 Technivie: 4

Yes

AbbVie

Zepatier

elbasvir,  (EBR)

Approved

1 4

Yes

Merck

Epclusa

velpatasvir,  (VEL)

Approved

1 2 3 4 5 6

Yes

Gilead Sciences

Mavyret

pibrentasvir,

(P)

APPROVED

1 2 3 4 5 6

Yes

AbbVie

Non-nucleoside NS5B polymerase inhibitors

Viekira XR

dasabuvir,
(DAS)

Approved

1

Yes

AbbVie